ePharma Summit discusses the future

Share this article:
The future of e-marketing will be in focus from Jan. 28- Jan. 30 when the some of the top names in e-marketing gather at Philadelphia's Ritz Carlton Hotel for the Institute for International Research's seventh annual ePharma Summit.
“2007 proved to be the year that pharmaceutical e-marketing reached the tipping point, where it became a key part of the brand marketing mix, and where budget allocations grew at unprecedented rates,” said Paul Ivans, president of Evolution Road and ePharma Summit chairman. “Now it's time for us to ramp up the scale of our e-marketing efforts to impact topline sales for our brands, and help massive numbers of consumers and physicians make better, more informed healthcare choices at the same time.”

Ivans will be among the featured speakers which include: AOL co-founder/Revolution Health CEO Steve Case; Google's health industry manager Khee Lee; Microsoft's Health Solutions VP Peter Neupert; Wyeth e-marketer Nancy Phelan; Shire e-marketing director Bob Harrell; Novartis head of
interactive marketing Stephen Calabrese; WEGO Health CEO Jack Barrette; aQuantive EVP Brad Aronson; and Sermo CEO Daniel Palestrant, MD. For more information, visit www.epharma

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?